Answers are grounded in this paper and cite their sources.
As compared with intravenous paclitaxel plus cisplatin, intravenous paclitaxel plus intraperitoneal cisplatin and paclitaxel improves survival in patients with optimally debulked stage III ovarian cancer.
No takes yet. Share an insight, caveat, or question.
Armstrong et al. (2006) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: